Showing 1 - 3 results of 3 for search 'John E. Janik', query time: 0.03s Refine Results
  1. 1
    Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma

    Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma by Andrey Moiseyenko, Franco Muggia, Thomas Condamine, Jennifer Pulini, John E. Janik, Daniel C. Cho

    Published 2020-11-01
    Get full text
    Article
  2. 2
    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors by Rebecca Kristeleit, Juan Martin-Liberal, Kristen Spencer, Janice M Mehnert, Maria Vieito, Elizabeth J Davis, Angela Orcurto, Thomas Condamine, Daniel C Cho, Jennifer Pulini, Rowan E Miller, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Prashanth Hari Dass, John E Janik, Jason Clark, Xuejun Chen

    Published 2022-10-01
    Get full text
    Article
  3. 3
    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors by Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif

    Published 2018-06-01
    Get full text
    Article

Search Tools: